Full Press Release Details
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates.
CRVO
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Key Takeaway: CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Price reaction · baseline $24.7 (2024-05-14 close) · hit after-hours · 1 other CRVO headline(s) in the window, move may be shared
day 0 close
+0.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
6.8%
average across 6 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
Neflamapimod
Phase 2 · Moderate to Severe Acute Ischaemic Stroke